| Literature DB >> 34337053 |
Irina N Saburina1, Irina M Zurina1,2, Nastasia V Kosheleva1,2,3, Anastasiya A Gorkun1,2, Elena N Volkova1, Olga S Grinakovskaya1, Anton S Rybakov1, Anna L Kaysheva4, Arthur T Kopylov4, Sergey G Morozov1.
Abstract
Meso-Xanthin (Meso-Xanthin F199™) is a highly active antiaging injection drug of the latest generation. The main acting compound is fucoxanthin, supplemented with several growth factors, vitamins, and hyaluronic acid. Previous examination of fucoxanthin on melanocytes showed its ability to inhibit skin pigmentation through different signaling pathways focused on suppression of melanogenic-stimulating receptors. In turn, the anticancer property of fucoxanthin is realized through MAPK and PI3K pathways. We aimed to evaluate the effect of fucoxanthin and supplemented growth factors on melanocyte growth and transformation at a proteomic level. The effect of fucoxanthin on melanocytes cultivated in three-dimensional (3D) condition was examined using high-throughput proteomic and system biology approaches to disclose key molecular events of the targeted action. Our results demonstrated significant inhibition of cell differentiation and ubiquitination processes. We found that the negative regulation of PSME1 and PTGIS largely determines the inhibition of NF-κB and MAPK2. Besides, fucoxanthin selectively inhibits cell differentiation via negative regulation of Raf signaling and the upstream activation of IL-1 signaling. It is assumed that inhibition of Raf influences the Notch-4 signaling and switches off the MAPK/MAPK2 cascade. Blockage of MAPK/MAPK2 is feasible due to suppression of Ras and NF-κB by the addressed action of IKKB, IKK2, and TRAF6. Suggestively, Meso-Xanthin F199™ can manage processes of proliferative activity and inhibition of apoptosis due to composition of fucoxanthin and growth-stimulating factors, which may increase the risk of skin cancer development under certain condition.Entities:
Year: 2021 PMID: 34337053 PMCID: PMC8315846 DOI: 10.1155/2021/8463161
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1Morphology of melanocytes in 2D and 3D cell cultures. In passage 4, the culture of human melanocytes was represented by cells with spindle-shaped or dendritic cells (a). Cells in nonadhesive microwells formed dark compact spheroids both in control growth medium (b) and in the presence of Meso-Xanthin F199™ (c). Light phase-contrast microscopy.
Figure 2Descriptive primary analysis of the obtained proteomes among studied melanocyte cells cultivated in a monolayer and in spheroids before and after exposure to FX (a). Protein distribution among studied human melanocyte cultures. The total size of the significantly contributing proteome was 434 protein identifications, which is about 19% of the individual proteome of each sample. (b) Distribution of the symmetry coefficient dependent on the cumulative number of protein identifications. The maximum increase in the symmetry coefficient is observed with the accumulation of 80%-87% of the summarized size of the proteome. Most of the identified proteins among studied melanocyte samples make an insignificant contribution to the growth of the asymmetry of the distribution (up to 0.0025 units per protein).
Figure 3Heatmap of semiquantitative protein distribution in the shared proteome for M2319, Nm01, and Am02 melanocytes. The sample M2319 was employed as a baseline for normalization. Range correlation of proteins was performed using Spearman's test. The total size of the tested proteome involved 434 protein identifications. Samples Nm01 and Am02 are at the closest localization according to the results of cluster analysis, while M2319 is the most distal.
Figure 4Network interaction analysis of proteins with positive regulation in cells before (Nm01) and after (Am02) exposure to Meso-Xanthin F199. The resulting network establishes interactions in the streamlining processes of cell response to stimulation and activation of RNA metabolism. The background biological processes actively undergoing after exposure to Meso-Xanthin are a response to stimulation (GO: 0051716, p = 0.0088), which reflects changing the state and activity of the cell (including gene expression, secretion, and enzymatic activity) and the closely related process of signal transmission (GO: 0007165, p = 0.0131). In general, these biological processes agree well with those molecular functions that have been identified in this study (protein binding and protein metabolism and RNA binding and metabolism). In addition, groups of proteins with phosphatase and GTPase activity (GO: 0003924, p = 0.0105), which are upstream to protein metabolism actively involved in translation and assembly of ribonucleoproteins, were also identified in this network.
The most significantly differed proteins exhibited in the primary culture of human melanocytes cultured under three-dimensional condition (spheroids) for 7 days and exposed to 50 μM equivalent of FX (Am02) or treated with saline solution (Nm01).
| Main accession | Recommended protein name | Gene | Ensembl gene ID | Nm-01, FC | Am-02, FC |
|
|---|---|---|---|---|---|---|
| Q06323 | Proteasome activator complex subunit 1 | PSME1 | ENSG00000092010 | 0.38 | 0.12 | 6.05 |
| Q99466 | Neurogenic locus notch homolog protein 4 | NOTCH4 | ENSG00000204301 | 1.17 | 0.18 | 2.59 |
| Q14203 | Dynactin subunit 1 | DCTN1 | ENSG00000204843 | 0.64 | 0.20 | 3.98 |
| P49137 | MAP kinase-activated protein kinase 2 | MAPKAPK2 | ENSG00000162889 | 1.12 | 0.22 | 3.62 |
| Q16181 | Septin-7 | 07-Sep | 0.75 | 0.29 | 5.50 | |
| P35232 | Prohibitin | PHB | ENSG00000167085 | 0.60 | 0.30 | 1.38 |
| P55795 | Heterogeneous nuclear ribonucleoprotein H2 | HNRH2 | ENSG00000126945 | 0.37 | 0.31 | 5.10 |
| Q15121 | Astrocytic phosphoprotein PEA-15 | PEA15 | ENSG00000162734 | 0.29 | 0.32 | 1.34 |
| Q14247 | Src substrate cortactin | SRC8 | ENSG00000085733 | 1.62 | 0.33 | 1.71 |
| Q16647 | Prostacyclin synthase | PTGIS | ENSG00000124212 | 0.66 | 0.36 | 3.17 |
| Q15149 | Plectin | PLEC | ENSG00000178209 | 0.20 | 0.40 | 1.25 |
| P63208 | S-phase kinase-associated protein 1 | SKP1 | ENSG00000113558 | 0.40 | 0.40 | 6.57 |
| P61978 | Heterogeneous nuclear ribonucleoprotein K | HNRPK | ENSG00000165119 | 0.64 | 0.41 | 3.28 |
| P14866 | Heterogeneous nuclear ribonucleoprotein L | HNRPL | ENSG00000282947 | 0.84 | 0.43 | 3.34 |
| P31946 | 14-3-3 protein beta/alpha | 1433B | ENSG00000166913 | 0.71 | 0.50 | 4.11 |
| Q00839 | Heterogeneous nuclear ribonucleoprotein U | HNRPU | ENSG00000153187 | 0.91 | 0.50 | 1.45 |
| Q92499 | ATP-dependent RNA helicase DDX1 | DDX1 | ENSG00000079785 | 5.08 | 0.60 | 3.52 |
| Q99623 | Prohibitin-2 | PHB2 | ENSG00000215021 | 0.42 | 0.63 | 2.75 |
| O15145 | Actin-related protein 2/3 complex subunit 3 | ARPC3 | ENSG00000111229 | 2.70 | 1.03 | 2.05 |
| O15144 | Actin-related protein 2/3 complex subunit 2 | ARPC2 | ENSG00000163466 | 4.27 | 1.20 | 2.36 |
| P61224 | Ras-related protein Rap-1b | RAP1B | ENSG00000127314 | 7.98 | 1.20 | 2.00 |
| Q13200 | 26S proteasome non-ATPase regulatory subunit 2 | PSMD2 | ENSG00000175166 | 2.19 | 1.37 | 2.46 |
| P52272 | Heterogeneous nuclear ribonucleoprotein M | HNRPM | ENSG00000099783 | 2.62 | 1.45 | 9.07 |
| Q04917 | 14-3-3 protein eta | 1433F | ENSG00000128245 | 2.65 | 1.53 | 1.14 |
| P10415 | Apoptosis regulator Bcl-2 | BCL2 | ENSG00000171791 | 0.73 | 1.78 | 3.69 |
| P40121 | Macrophage-capping protein | CAPG | ENSG00000042493 | 2.32 | 1.79 | 8.15 |
| P42224 | Signal transducer and activator of transcription 1-alpha/beta | STAT1 | ENSG00000115415 | 1.32 | 1.84 | 1.10 |
| P31152 | Mitogen-activated protein kinase 4 | MAPK4 | ENSG00000141639 | 0.68 | 1.92 | 3.38 |
| P46531 | Neurogenic locus notch homolog protein 1 | NOTCH1 | ENSG00000148400 | 0.66 | 2.13 | 6.71 |
| Q15019 | Septin-2 | SEPT2 | 1.05 | 2.15 | 7.20 | |
| P31943 | Heterogeneous nuclear ribonucleoprotein H | HNRH1 | ENSG00000169045 | 0.68 | 2.21 | 4.35 |
| P04792 | Heat shock protein beta-1 | HSPB1 | ENSG00000106211 | 1.48 | 2.34 | 5.16 |
| P17980 | 26S proteasome regulatory subunit 6A | PRS6A | ENSG00000165916 | 0.48 | 2.39 | 4.92 |
| P08670 | Vimentin | VIME | ENSG00000026025 | 0.98 | 2.61 | 3.29 |
| P46940 | Ras GTPase-activating-like protein IQGAP1 | IQGA1 | ENSG00000140575 | 2.33 | 2.68 | 2.60 |
| Q9UBI6 | Guanine nucleotide-binding protein G/G/G subunit gamma-12 | GBG12 | ENSG00000172380 | 1.29 | 2.73 | 2.36 |
| P78504 | Protein jagged-1 | JAG1 | ENSG00000101384 | 0.97 | 2.98 | 4.27 |
| P43686 | 26S proteasome regulatory subunit 6B | PRS6B | ENSG00000281221 | 1.45 | 2.99 | 2.70 |
| Q6NZI2 | Caveolae-associated protein 1 | CAVN1 | ENSG00000177469 | 1.82 | 3.56 | 2.95 |
| O95782 | AP-2 complex subunit alpha-1 | AP2A1 | ENSG00000196961 | 5.14 | 3.59 | 1.78 |
| O60701 | UDP-glucose 6-dehydrogenase | UGDH | ENSG00000109814 | 0.40 | 5.54 | 3.40 |
| P60953 | Cell division control protein 42 homolog | CDC42 | ENSG00000070831 | 2.14 | 5.78 | 9.38 |
| Q03135 | Caveolin-1 | CAV1 | ENSG00000105974 | 5.32 | 6.18 | 7.20 |
| P07996 | Thrombospondin-1 | TSP1 | ENSG00000137801 | 3.95 | 6.58 | 1.34 |
| P62873 | Guanine nucleotide-binding protein G/G/G subunit beta-1 | GBB1 | ENSG00000078369 | 1.30 | 20.80 | 3.15 |
Figure 5Dynamic alterations of Rap1- and MAPK4/MAPK6-related proteins overlapped between analyzed melanocytes. Proteins regulating the activity of MAPK4 and MAPK6 kinases (PRS6A, PRS6B, PRS7, and PSMD2) are characterized by the maximum abundancy in the Am02 culture (after exposure to FX) and significantly decreased in Nm01 melanocytes. The RAP1B protein switching between different signaling cascades takes the most abundance in samples Nm01 and M2319 and is strongly inhibited in Am02 melanocytes after exposure to FX.
Figure 6Comprehensive interaction of plenty proteins in signaling pathways inhibited by FX exposure. The protein PSME1 is one of the main regulators of IL-1, in response to which, in turn, the expression of PTGIS is enhanced. The interaction of IL-1 with its single receptor IL1R causes the dissociation of IRAK1 and IRAK4 from the complex with Myd88 and the assembling of a molecular complex with IL-1. This complex, in turn, activates TRAF6, which starts the process of its autoubiquitination. Being in such modified form, TRAF6 interacts with TAK1, which has to be already activated by the TGF-β factor. After interaction and activation, TAK1 is bound to a complex of TAK2 and TAK3 subunits and such molecular machinery enhances the expression of the NF-κB inhibitors, like IKK2 and IKKB. On the other hand, PSME1 is a regulator of the Raf-MAPK pathway where IL-1 interacts with Ras surface receptors and, thus, activates its cytoplasmic GEF domain. Activated RAF with GTP can interfere with the YWHAB dimer, and the PHB factor initiates their rearrangement and further heterodimerization, which is the starting point for triggering the MAPK/MAPK2 signaling pathway.